FierceBiotech 20. Apr. 2026 Novo readies SCD drug from $1.1B Forma buyout for approval push after phase 3 win
FierceBiotech 20. Apr. 2026 Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
FierceBiotech 20. Apr. 2026 Biogen inks $850M biobucks deal with TJ Biopharma for China rights to late-stage immune antibody
FierceBiotech 20. Apr. 2026 Agenus focuses on survival data as 0% response rate triggers primary miss
FierceBiotech 20. Apr. 2026 Odyssey charts fresh voyage to public markets after abandoning IPO plans last year
FierceBiotech 20. Apr. 2026 AstraZeneca’s faith in IL-33 inhibitor continues to pay off with latest phase 3 COPD win
FierceBiotech 20. Apr. 2026 How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients
FierceBiotech 20. Apr. 2026 FDA celebrates progress to end animal testing but experts warn there’s still a long way to go
FierceBiotech 20. Apr. 2026 AACR: Former Genentech leader engineers startup with vision for ‘smart’ cancer drugs
FierceBiotech 18. Apr. 2026 AACR: FDA vet Pazdur bemoans state of agency, warns of political influence and ‘sense of anxiety’
FierceBiotech 17. Apr. 2026 UCB pays $650M+ for Neurona, marking 'strategic expansion' into regenerative medicine
FierceBiotech 17. Apr. 2026 Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans